Friday, 16 October 2026European Markets

AKASTOR Stock Over 10% Up So Far Today

Loading stream...

(VIANEWS) - Shares of AKASTOR (Oslo Børs Benchmark Index_GI: AKAST.OL) jumped by a staggering 10.89% to kr11.20 at 14:25 EST on Thursday, after two consecutive sessions in a row of gains. Oslo Børs Benchmark Index_GI is rising 0.69% to kr1,206.97, following the last session's upward trend. This seems, as yet, a somewhat bullish trend exchanging session today.

AKASTOR's last close was kr10.32, 27.02% below its 52-week high of kr14.14.

About AKASTOR

Akastor ASA operates as an oilfield services investment company in Norway, the United Kingdom, Denmark, Australia, and internationally. The company offers vessel-based subsea well construction and intervention services to the oil and gas industry. It also provides well design and drilling project management services; reservoir and field management services; and rig procurement, tailored training, software, and technical manpower services, as well as well and reservoir consultancy services. In addition, the company offers a range of offshore drilling equipment products and packages. It owns five offshore vessels. Akastor ASA was founded in 1841 and is based in Bærum, Norway.

Earnings Per Share

As for profitability, AKASTOR has a trailing twelve months EPS of kr-0.62.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -3.76%.

Volume

Today's last reported volume for AKASTOR is 408269 which is 107.32% above its average volume of 196927.

Earnings Before Interest, Taxes, Depreciation, and Amortization

AKASTOR's EBITDA is -431.5.

Growth Estimates Quarters

The company's growth estimates for the present quarter is 92.3% and a drop 54.2% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, AKASTOR's stock is considered to be oversold (<=20).

More news about AKASTOR (AKAST.OL).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com